CVS Health has just faced a stock decline of about 10% after its preliminary Q3 earnings miss, which made the entire market aware. The decline is contributed largely to a $1.1 billion charge connected with its Medicare and Individual Exchange businesses and a whopping $1.2 billion restructuring charge for store closures.Read more

Key Takeaways Strong performance in immunology and neuroscience, supported by new product launches and expanding indications, helps offset losses from older drugs facing competition. Strategic pipeline development, international growth, and operational efficiency position the company to sustain profitability and adapt to evolving industry trends.Read more